Skip to main content
HR 113 117th Congress House Health Cancer Government information and archives Health information and medical records Health programs administration and funding Health promotion and preventive care Medical education Medical research Minority health Research administration and funding Women's health

Triple-Negative Breast Cancer Research and Education Act of 2021

Introduced: January 4, 2021 See on congress.gov
Sign in to write a letter Sign in to watch
 Everywhere this bill has been 3 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Feb 2, 2021
Referred to the Subcommittee on Health.
Jan 4, 2021
Referred to the House Committee on Energy and Commerce.
Jan 4, 2021
Introduced in House
 Plain-English summary Congressional Research Service

Triple-Negative Breast Cancer Research and Education Act of 2021

This bill requires research and education activities related to triple-negative breast cancer. The cells of these breast cancers are negative for estrogen receptors, progesterone receptors, and excess HER2 protein, so they do not respond to hormonal therapy medicines or medicines that target the HER2 protein receptors.

Specifically, the National Institutes of Health must conduct and support research into the disease.

Additionally, the Centers for Disease Control and Prevention and the Health Resources and Services Administration must develop information about triple-negative breast cancer, including information regarding the elevated risk for minority women, for the public and for health care providers.

What's happening now February 2, 2021

Referred to the Subcommittee on Health.

 Committees of jurisdiction 2
 Cosponsors 1
All 1 Democratic 1